Lundbeck Limited, A Menarini Pharma, Bayer plc, HRA Pharma UK and GlaxoSmithKline have each breached Clause 2 of the ABPI Code of Practice and are the subject of advertisements in the medical, pharmaceutical and nursing press.
Lundbeck – Case AUTH/2617/7/13
A Menarini – Case AUTH/2629/8/13
Bayer plc – Case AUTH/2631/8/13
For each sponsoring one or two speakers and paying for exhibition space at a meeting which was not primarily for educational purposes and the impression given by their involvement, each company was ruled in breach of the following clauses of the Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 9.1 - Failing to maintain high standards
Clause 19.1 - Failing to meet the requirements for meetings.
HRA Pharma UK – Case AUTH/2624/8/13
As a result of emails sent by a representative to a health professional regarding the provision of an emergency contraception service and the use of ellaOne (ulipristal acetate), HRA Pharma was ruled in breach of the following clauses of the Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 7.2 - Making a misleading claim
Clause 7.10 - Making an exaggerated claim
Clause 8.2 - Disparaging a service provision
Clause 9.1 - Failing to maintain high standards
Clause 15.2 - Failing to maintain a high standard of ethical conduct.
GlaxoSmithKline – Case AUTH/2649/10/13
As a result of a voluntary admission that it had not formally certified materials relating to a joint working project with the NHS until some months after the project had started, GlaxoSmithKline was ruled in breach of the following clauses of the Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 9.1 - Failing to maintain high standards
Clause 14.3 - Failing to certify joint working materials before use.
http://www.pmcpa.org.uk/media/pages/lundbeck-limited,-a-menarini-pharma,-bayer-plc,-hra-pharma-uk-and-glaxosmithkline-named-in-advertisements-for-breaches-of-t.aspx
No comments:
Post a Comment